For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

MORE Tumor Response:

Delivered a ≥30% Reduction in Tumors in 3X More mCRPC Patients

Secondary Endpoint: Investigator-assessed Tumor Response1-4

JEVTANA 25 mg/m2 + prednisone (n=201) (95% CI: 9.6 - 19.3)
mitoxantrone + 
prednisone (n=204)
(95% CI: 1.6 - 7.2)
14.4%
4.4%
P=0.0005
≥30% reduction in tumors in 3X more mCRPC patients
  • Partial response was measured by RECIST criteria, which is defined as at least a 30% decrease in the sum of diameters of target lesions, compared to baseline.4

JEVTANA IS A NCCN designated CATEGORY 1 SECOND-LINE THERAPY FOR mCRPC5

VIEW TRIALS &
PATIENTS STUDIED

IMPORTANT SAFETY INFORMATION

WARNING: NEUTROPENIA AND HYPERSENSITIVITY

  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave jevtanapro.com


You are leaving jevtanapro.com to view another Sanofi Genzyme Corporation website.



Continue 
Cancel